Exhibit 16.1
July 26, 2023
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
We have read Vaxxinity, Inc.’s statements included in Item 4.01 of its Current Report Form 8-K dated July 26, 2023
and agree with those statements concerning our firm. We have no basis to agree or disagree with other statements of
the registrant contained therein.
/s/ Armanino LLP
